← Back to Search

Other

INV-202 for Metabolic Syndrome

Phase 1
Waitlist Available
Research Sponsored by Inversago Pharma Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Provision of a signed and dated informed consent form (ICF).
Willing and able to comply with all study procedures for the duration of the study.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

Study Summary

This trial is testing a new drug, INV-202, to see if it is safe and effective in people with metabolic syndrome.

Eligible Conditions
  • Metabolic Syndrome

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number and Frequency of Adverse Events
Secondary outcome measures
Pharmacokinetic profile of INV-202

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: INV-202Experimental Treatment1 Intervention
INV-202 25mg by mouth once daily
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo by mouth once daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
INV-202
2022
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

Inversago Pharma Inc.Lead Sponsor
3 Previous Clinical Trials
523 Total Patients Enrolled
1 Trials studying Metabolic Syndrome
243 Patients Enrolled for Metabolic Syndrome
Glenn D Crater, MDStudy DirectorInversago Pharma
1 Previous Clinical Trials
40 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome
2022. "A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05282446.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top